ELUTIA INC. - CLASS A COMMON STOCK

Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company’s Antibiotic-Eluting BioEnvelope for Implantable Devices

18 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Elutia Celebrates First Year

06 9 2024 16:23:52 提供 Nasdaq GlobeNewswire

Elutia Announces First Patient Implant of EluPro™, the World’s First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators

05 9 2024 16:05:00 提供 Nasdaq GlobeNewswire

Elutia to Participate in Upcoming Investor Conferences

03 9 2024 16:05:00 提供 Nasdaq GlobeNewswire

Elutia Announces Second Quarter 2024 Results

07 8 2024 16:05:01 提供 Nasdaq GlobeNewswire

Elutia Announces Full Exercise of Warrants Generating $15.7 Million in Gross Proceeds

01 8 2024 16:05:00 提供 Nasdaq GlobeNewswire

Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

31 7 2024 16:05:00 提供 Nasdaq GlobeNewswire

Elutia to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

30 7 2024 16:05:00 提供 Nasdaq GlobeNewswire

Elutia to Present at the Emerging Growth Conference on Thursday, July 18

11 7 2024 16:05:00 提供 Nasdaq GlobeNewswire

Elutia Announces $13.26 Million Registered Direct Offering

17 6 2024 08:01:00 提供 Nasdaq GlobeNewswire

Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators

17 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

Elutia to Showcase BioEnvelope Product Line at Heart Rhythm 2024

13 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Elutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA Clearance

09 5 2024 16:05:01 提供 Nasdaq GlobeNewswire

Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

02 5 2024 16:05:00 提供 Nasdaq GlobeNewswire

Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1

24 4 2024 16:05:00 提供 Nasdaq GlobeNewswire

Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024

22 2 2024 16:05:00 提供 Nasdaq GlobeNewswire

Elutia Regains Compliance with Nasdaq Listing Requirements

10 1 2024 16:05:00 提供 Nasdaq GlobeNewswire

Elutia Submits CanGarooRM® Antibiotic-Eluting Biomatrix for FDA Clearance

18 12 2023 08:00:00 提供 Nasdaq GlobeNewswire

Elutia Reports 26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial Results

13 11 2023 16:05:01 提供 Nasdaq GlobeNewswire

Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million

09 11 2023 08:30:00 提供 Nasdaq GlobeNewswire